Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 76 publications.

Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial. Cancer. 2024 Oct 15;130(20):3426-35. doi: 10.1002/cncr.35438

Viguerie A, Jacobson EU, Hicks KA, Bates L, Carrico J, Honeycutt A, Lyles C, Farnham PG. Assessing the impact of COVID-19 on HIV outcomes in the United States: a modeling study. Sex Transm Dis. 2024 Apr 1;51(4):299-304. doi: 10.1097/OLQ.0000000000001935

Curtis R, Decker-Palmer M, Wilson MR, McDade CL, Lin CW, Wallick C, Ko RH. Cost-effectiveness of emicizumab vs efanesoctocog alfa, standard half life (SHL) and other extended half life (EHL) FVIII products for prophylaxis in people with severe hemophilia a without inhibitors. Poster presented at the 65th ASH Annual Meeting & Exposition 2023; December 11, 2023. San Diego, CA. [abstract] Blood. 2023 Nov; 142(Supplement 1):5053-4. doi: 10.1182/blood-2023-181062

Dorling P, Luzzi R, McMichael A, Kent C, Canty E, Myers K, Badawy SM. Patients' preferences for dosing frequency and out-of-pocket cost associated with iron chelators: a mixed-methods pilot study in the United States. Poster presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition; December 7, 2023. San Diego, CA. [abstract] Blood. 2023 Nov; 142(Suppl 1):7203. doi: 10.1182/blood-2023-186416

Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: a SEER-Medicare population-based study. Cancer. 2023 Apr 1;129(7):1051-63. doi: 10.1002/cncr.34675

Srivastava A, Rangarajan S, Ross C, Slota C, DiBenedetti D, Cano V, Andersson S, DasMahapatra P, Bartelt-Hofer J, Afonso M. Fitusiran reaches people's with hemophilia and their caregivers' treatment expectations: qualitative semi-structured interviews of participants of ATLAS-OLE Trial (Interim analysis). Poster presented at the American Society of Hematology (ASH) Annual Meeting 2022; December 11, 2022. New Orleans, LA. [abstract] Blood. 2022 Nov 15; 140(Suppl 1):7989-90. doi: 10.1182/blood-2022-166895

Garland SN, Savard J, Eisel SL, Wassersug RJ, Rockwood NJ, Thoms J, Jim HSL, Gonzalez BD. A 2‐year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer. Cancer. 2021 Dec 15;127(24):4656-64. doi: 10.1002/cncr.33850

Joly F, DasMahapatra P, Su J, DiBenedetti D, Kosa K, Hill Q. Development of a cold Agglutinin disease-specific patient-reported outcome symptom measure. Poster presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 13, 2021. [abstract] Blood. 2021 Nov 23; 138(supplement 1):4057. doi: 10.1182/blood-2021-147199

Walters MC, Tisdale JF, Mapara MY, Krishnamurti L, Kwiatkowski JL, Aygun B, Kasow KA, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher ME, Zhang X, Ho PR, Thompson AA, Kanter J. Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy. Presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 11, 2021. Atlanta, Georgia. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):7. doi: 10.1182/blood-2021-146905

Germing U, Goyal RK, Yucel A, Parikh RC, Jimenez M, Sluga-O'Callaghan M, Tang D, Hughes C, Diez-Campelo M. Real-world evidence on treatment utilization in lower-risk myelodysplastic syndromes: findings from a medical record review in the United States. Poster presented at the 63rd ASH Annual Meeting and Exposition; December 11, 2021. Atlanta, GA. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):4666. doi: 10.1182/blood-2021-145576

Anderson S, Talbird S, Fishman J. Cost per responder analysis for pegcetacoplan and eculizumab in the treatment of adults with paroxysmal nocturnal hemoglobinuria. Blood. 2021;138(Suppl 1):4956. doi: 10.1182/blood-2021-153190

Sun SX, Olayinka-Amao O, DiBenedetti D. Assessing patient experiences with prophylactic treatments for hemophilia A: concept elicitation for gene therapy. Poster presented at the 62nd Annual Virtual Meeting of the American Society of Hematology (ASH); December 5, 2020. [abstract] Blood. 2020 Nov 5; 136(Suppl 1):33-4.

Spira AI, Chen L, Zhou X, Gnanasakthy A, Wang L, Ungar D, Curiel R, Radford JA, Kahl BS. Symptoms, health-related quality of life, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large b cell lymphoma. Blood. 2020 Nov 5;136(Suppl 1):3-4. doi: 10.1182/blood-2020-139571

Su J, Kosa K, DiBenedetti D. Patient-reported disease burden: in-depth interviews of patients with CAD. Poster presented at the 2020 Virtual 62nd ASH Annual Meeting and Exposition; December 6, 2020. [abstract] Blood. 2020 Nov 5; 136(Suppl 1):29-30.

Cohen AD, Hari P, Htut M, Berdeja JG, Madduri D, Usmani SZ, Allred AJ, Olyslager Y, Banerjee A, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau J, Deraedt W, Carrasco MJ, Akram M, Hossain F, Crawford R, Morrison R, Doward L, Jakubowiak A, Jagannath S. Patient expectations and perceptions of treatment in cartitude-1: phase 1b/2 study of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma. Poster presented at the 62nd Annual Virtual Meeting of the American Society of Hematology (ASH); December 2020. [abstract] Blood. 2020 Nov; 136(Suppl 1):13-6. doi: 10.1182/blood-2020-136383

Meernik C, Kirchhoff AC, Anderson C, Edwards TP, Deal AM, Baggett CD, Kushi LH, Chao CR, Nichols HB. Material and psychological financial hardship related to employment disruption among female adolescent and young adult cancer survivors. Cancer. 2020 Jan 1;127(1):137-48. doi: 10.1002/cncr.33190

Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841

Allen LF, Aggarwal K, Vredenburg M, Barnett C, Mladsi D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 61st ASH American Society of Hematology Annual Meeting and Exposition; December 8, 2019. San Diego, CA. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):3454. doi: 10.1182/blood-2019-131822

Houghton K, Dimopoulos M, Lin PL, Guillonneau S, Bury S, Attal M, Richardson PG, Delforge M. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with isatuximab plus pomalidomide and dexamethasone: Icaria-MM study. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):1850. doi: 10.1182/blood-2019-128220

Goyal RK, Nagar SP, Kabadi SM, Davis KL, Le H, Kaye JA. Overall survival, adverse events, and economic burden in Medicare patients with chronic lymphocytic leukemia receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement 1):796. doi: 10.1182/blood-2019-122842

Dawson KL, Price MA, Torney PA, Gonzalez V, Sae-Hau M, Weiss E, Mange B, Mansfield C, Comenencia-Ortiz E, Masaquel A, Ravelo A. Patient-reported disease burden and age: results from a national patient advocacy survey of patients with chronic lymphocytic leukemia, diffuse large-B-cell lymphoma and follicular lymphoma. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):4778. doi: 10.1182/blood-2019-123644

Xie J, Yong A, Waweru C, Sorof TA, Goyal RK, Davis KL, Fellows G, Hillmen P. Real-world treatment patterns and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib in the UK: a preliminary analysis. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):5885. doi: 10.1182/blood-2019-123025

Olivieri M, Murgia N, Carsin AE, Heinrich J, Benke G, Bono R, Corsico AG, Demoly P, Forsberg B, Gislason T, Janson C, Jogi R, Leynaert B, Rovira JM, Norback D, Nowak D, Pascual S, Pin I, Probst-Hensch N, Raherison C, Sigsgaard T, Svanes C, Toren K, Urrutia I, Weyler J, Jarvis D, Zock JP, Verlato G. Effects of smoking bans on passive smoking exposure at work and at home. The European Community respiratory health survey. Indoor Air. 2019 Jul;29(4):670-9. doi: 10.1111/ina.12556

Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Murthy S, Verma A, Shastri A. Risk stratification and transfusion dependence are independent risk factors for cardiovascular disease (CVD) in myelodysplastic syndrome (MDS). Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; November 13, 2019. [abstract] Blood. 2019; 134(Suppl 1):336. doi: 10.1182/blood-2019-123317

Auclair D, Mansfield C, Chari A, Cole CE, Fiala MA, Kaufman JL, Orloff G, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Patient treatment preferences for relapsed/refractory multiple myeloma: are patients willing to trade off efficacy for tolerability? Presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; December 3, 2018. San Diego, CA. [abstract] Blood. 2018 Nov 29; 132(Supplement 1):614. doi: 10.1182/blood-2018-99-113087

Kabadi S, Goyal RK, Nagar SP, Kaye JA, Davis KL, Mato A. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2, 2018. San Diego, CA. [abstract] Blood. 2018 Nov 29; 132(Supplement 1):3557. doi: 10.1182/blood-2018-99-114735

Park EM, Deal AM, Yopp JM, Edwards T, Resnick SJ, Song MK, Nakamura ZM, Rosenstein DL. Understanding health-related quality of life in adult women with metastatic cancer who have dependent children. Cancer. 2018 Jun 15;124(12):2629-36. doi: 10.1002/cncr.31330

Barnett CL, Auffenberg GB, Cheng Z, Yang F, Wang J, Wei JT, Miller DC, Montie JE, Mamawala M, Denton BT. Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies. Cancer. 2018 Feb 15;124(4):698-705. doi: 10.1002/cncr.31101

Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Murthy S, Verma A, Shastri A. Myelodysplastic Syndromes (MDS) are an independent risk factor for an earlier onset of myocardial infarction and increased mortality from Cardiovascular Disease (CVD). Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; November 29, 2018. San Diego, CA. [abstract] Blood. 2018; 132(Suppl 1):3539. doi: 10.1182/blood-2018-99-115613

Karve S, Nagar S, Goyal R, Kaye JA, Mato AR. Adverse events, resource use, and economic burden in patients with mantle cell lymphoma in the United States. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3442. doi: 10.1182/blood.V130.Suppl_1.3442.3442

Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Castor Trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3400. doi: 10.1182/blood.V130.Suppl_1.3400.3400

Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Pollux trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 11, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):4711. doi: 10.1182/blood.V130.Suppl_1.4711.4711

Goyal R, Karve S, Nagar S, Kaye JA, Mato AR. Real-world treatment patterns and associated adverse events among patients with mantle cell lymphoma (MCL) in the United States. Blood. 2017 Dec;130(Suppl 1):5650. doi: 10.1182/blood.V130.Suppl_1.5650.5650

Panella P, Casas M, Donaire‐Gonzalez D, Garcia‐Esteban R, Robinson O, Valentín A, Gulliver J, Momas I, Nieuwenhuijsen M, Vrijheid M, Sunyer J. Ultrafine particles and black carbon personal exposures in asthmatic and non-asthmatic children at school age. Indoor Air. 2017 Sep;27(5):891-9. doi: 10.1111/ina.12382

Norback D, Zock JP, Plana E, Heinrich J, Tischer C, Jacobsen R, Sunyer J, Kunzli N, Villani S, Olivieri M, Verlato G, Soon A, Schlunssen V, Gunnbjornsdottir MI, Jarvis D. Building dampness and mould in European homes in relation to climate, building characteristics and socio-economic status: the European Community Respiratory Health Survey ECRHS II. Indoor Air. 2017 Sep;27(5):921-32. doi: 10.1111/ina.12375

Sharp L, McDevitt J, Brown C, Carsin AE, Comber H. Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: results from a population-based analysis of 10,794 cases. Cancer. 2017 Jul 1;123(13):2543-50. doi: 10.1002/cncr.30583

Mansfield C, Masaquel A, Sutphin J, Weiss ES, Gutierrez ME, Wilson J, Li J, Reyes C. What do patients prioritize in selecting chronic lymphocytic leukemia (CLL) treatments? Presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2016. San Diego, CA. [abstract] Blood. 2016 Dec 2; 128(22):1239. doi: 10.1182/blood.V128.22.1239.1239

Lin HM, Davis KL, Kaye JA, Luptakova K, Gao L, Nagar S, Seal B, Mohty M. Real-world clinical outcomes by cytogenetic risk category in relapsed or refractory multiple myeloma: evidence from a cohort review in France. Poster presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2016. San Diego, CA. [abstract] Blood. 2016 Dec 2; 128(22):4784. doi: 10.1182/blood.V128.22.4784.4784

Darden CM, Price MA, Kaye JA, Sherif BN, Marion S, Tzivelekis S, Garcia J, Chandler D. Same-day administration of pegfilgrastim following myelosuppressive chemotherapy: practices and rationale. Blood. 2015 Dec 3;126(23):5585. doi: 10.1182/blood.V126.23.5585.5585

Kohler RE, Goyal RK, Lich KH, Domino ME, Wheeler SB. Association between medical home enrollment and health care utilization and costs among breast cancer patients in a state Medicaid program. Cancer. 2015 Nov 15;121(22):3975-81. doi: 10.1002/cncr.29596

Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611

Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA. Universal tumor screening for Lynch syndrome: assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer. 2015 Sep 15;121(18):3281-9. doi: 10.1002/cncr.29470

Davis KL, Cote I, Kaye JA, Gao H, Perez Ronco J, Seifeldin R, Mendelson E. Real-world assessment of clinical outcomes in lower-risk myelofibrosis patients receiving treatment with ruxolitinib. Poster presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; December 6, 2014. San Francisco, CA. [abstract] Blood. 2014 Dec 6; 124(21):1857. doi: 10.1182/blood.V124.21.1857.1857

Casulo C, Byrtek M, Dawson K, Zhou X, Flowers C, Farber C, Hainsworth J, Cerhan J, Link B, Friedberg J. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National LymphoCare Study. Poster presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2014. San Francisco, CA. [abstract] Blood. 2014 Dec 6; 124(21):3044. doi: 10.1182/blood.V124.21.3044.3044

Goyal R, Davis KL, Cote I, Mounedji N, Kaye JA. Increased incidence of thromboembolic event rates in patients diagnosed with polycythemia vera: results from an observational cohort study. Poster presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; December 6, 2014. San Francisco, CA. [abstract] Blood. 2014 Dec 6; 124(21):4840. doi: 10.1182/blood.V124.21.4840.4840

Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014 Jun 15;120(12):1830-7. doi: 10.1002/cncr.28659

Martin P, Byrtek M, Dawson K, Ziemiecki RM, Friedberg JW, Cerhan JR, Flowers CR, Link BK. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Cancer. 2013 Dec 1;119(23):4129-36. doi: 10.1002/cncr.28350

Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422

Clemens A, Abeysinghe S, Gonschior A-K, Hosel V, Lock S, Wolowacz SE, Woods M, Zimovetz E. Comparative efficacy and safety of dabigatran etexilate and rivaroxaban for the treatment of deep vein thrombosis and pulmonary embolism. Poster presented at the 55th ASH Annual Meeting; 2013. [abstract] Blood. 2013 Nov 15; 122(21):4807. doi: 10.1182/blood.V122.21.4807.4807